Cary Pfeffer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BioPharma

Arizona State University's independent student-run news organization covering Tempe, Phoenix, Mesa and Glendale.

Ralph Brandenberger,  Ph.D., to senior vice president, technical operations. Brandenberger joined the Nkarta team in 2018 and oversees the company's cell therapy manufacturing operations.  > Asklepios Biopharmaceutical tapped  Tracy Dowling as general counsel starting Jan. 25. Dowling will help manage and advise on corporate governance, business development transactions, license agreements, employment law and more. Most recently, Dowling served as associate general counsel at Spark Therapeutics.  > Precision oncology specialist OncoDNA signed on  Bernard Courtieu as CEO. Courtieu prev...

Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer Faze Medicines, a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Philip Vickers, Ph.D., as its chief executive officer (CEO). Dr. Vickers previously served as president and CEO of Northern Biologics and has worked in a diverse array of senior leadership roles across biotech and leading pharma companies. Dr. Vick...

Dive Brief: Dewpoint Therapeutics, a young drug company focused on an emerging field of research known as biomolecular condensates, said Wednesday that it is teaming up with Pfizer to develop new treatments for a rare kind of muscular dystrophy. Dewpoint will receive an initial payment and, provided certain goals are hit, could take home up to $239 million more. The biotech is also eligible to receive royalties on any approved products that stem from the collaboration. The companies' work will target myotonic dystrophy type 1, a genetic disease characterized by muscle wasting, problems in the...